(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of 97.56% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Meiragtx Holdings's revenue in 2025 is $34,508,000.On average, 2 Wall Street analysts forecast MGTX's revenue for 2025 to be $4,783,346,168, with the lowest MGTX revenue forecast at $830,977,812, and the highest MGTX revenue forecast at $8,735,714,523. On average, 2 Wall Street analysts forecast MGTX's revenue for 2026 to be $22,257,989,829, with the lowest MGTX revenue forecast at $22,005,642,601, and the highest MGTX revenue forecast at $22,510,337,056.
In 2027, MGTX is forecast to generate $14,042,239,178 in revenue, with the lowest revenue forecast at $14,042,239,178 and the highest revenue forecast at $14,042,239,178.